AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
AGIO on Nasdaq
Shares outstanding
58,643,980
Price per share
$27.22
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
63,494,336
Total reported value
$2,545,893,532
% of total 13F portfolios
0%
Share change
+1,630,536
Value change
+$81,769,913
Number of holders
216
Price from insider filings
$27.22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Farallon Capital Partners, L.P. 9.9% $166,034,875 5,674,466 Dapice Joshua J. 31 Dec 2024
BlackRock, Inc. 7.8% $150,100,362 4,513,170 BlackRock, Inc. 30 Jun 2025
Paradigm Biocapital Advisors LP 4.9% -6% $115,344,498 -$6,198,499 2,873,555 -5.1% Paradigm BioCapital Advisors LP 30 Sep 2025

As of 30 Sep 2025, 216 institutional investors reported holding 63,494,336 shares of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO). This represents 108% of the company’s total 58,643,980 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) together control 86% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FARALLON CAPITAL MANAGEMENT LLC 9.9% 5,781,066 +0.24% 1.3% $232,051,989
VANGUARD GROUP INC 9.6% 5,604,876 -1.4% 0% $224,979,722
BlackRock, Inc. 7.8% 4,545,738 -6% 0% $182,465,924
Bellevue Group AG 6.3% 3,714,736 +3.5% 3.1% $149,109,503
Erste Asset Management GmbH 4.7% 2,764,900 +19% 1% $108,577,623
Paradigm Biocapital Advisors LP 4.6% 2,673,555 +134% 3.2% $107,316,498
WELLINGTON MANAGEMENT GROUP LLP 4.2% 2,471,416 +485% 0.02% $99,202,637
Commodore Capital LP 4% 2,338,287 +0.57% 4.6% $93,858,840
STATE STREET CORP 3.9% 2,262,712 +16% 0% $90,825,260
MACQUARIE GROUP LTD 3.3% 1,958,101 +3% 0.09% $78,598,000
PRICE T ROWE ASSOCIATES INC /MD/ 2.8% 1,656,938 -27% 0.01% $66,510,000
TCG Crossover Management, LLC 2.4% 1,430,041 +105% 2.8% $57,401,846
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,416,315 +0.75% 0% $56,859,764
Frazier Life Sciences Management, L.P. 2.2% 1,279,754 0% 1.5% $51,369,326
Caligan Partners LP 1.9% 1,131,205 +5.6% 6.3% $45,406,569
BANK OF AMERICA CORP /DE/ 1.9% 1,130,000 +0.87% 0% $45,358,199
DIMENSIONAL FUND ADVISORS LP 1.7% 1,021,201 -7.7% 0.01% $40,987,144
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.7% 987,339 -2.9% 0.1% $39,631,000
Rock Springs Capital Management LP 1.6% 958,542 -3.2% 2.2% $38,475,876
DEUTSCHE BANK AG\ 1.6% 926,734 +0.56% 0.01% $37,199,103
Fisher Asset Management, LLC 1.5% 870,145 -0.84% 0.01% $34,927,619
GW&K Investment Management, LLC 1.5% 852,942 -1.8% 0.3% $34,238,000
GOLDMAN SACHS GROUP INC 1.4% 804,766 +24% 0% $32,303,307
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.4% 800,000 +1.1% 0.05% $32,112,000
ARMISTICE CAPITAL, LLC 1.3% 764,000 -35% 0.96% $30,666,960

Institutional Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 244,650 $6,658,627 -$189,808 $27.22 16
2025 Q3 63,494,336 $2,545,893,532 +$81,769,913 $40.14 216
2025 Q2 61,683,672 $2,051,725,997 +$65,237,829 $33.26 211
2025 Q1 59,963,279 $1,757,322,194 -$10,187,060 $29.30 216
2024 Q4 59,832,436 $1,966,429,716 +$37,958,970 $32.86 221
2024 Q3 58,096,571 $2,582,267,784 -$8,181,474 $44.43 204
2024 Q2 58,132,966 $2,506,935,894 -$125,225,015 $43.12 203
2024 Q1 61,946,791 $1,811,267,450 +$89,235,062 $29.24 183
2023 Q4 59,884,422 $1,333,701,271 +$15,853,345 $22.27 167
2023 Q3 59,110,077 $1,463,036,585 -$8,921,651 $24.75 142
2023 Q2 59,366,269 $1,679,785,246 +$16,420,594 $28.32 150
2023 Q1 58,996,438 $1,355,139,176 -$9,985,145 $22.97 161
2022 Q4 59,442,573 $1,669,125,079 +$45,133,345 $28.08 156
2022 Q3 57,972,960 $1,639,524,356 -$46,396,034 $28.28 155
2022 Q2 59,017,906 $1,308,562,484 -$21,425,021 $22.17 143
2022 Q1 59,895,743 $1,743,443,247 +$19,219,573 $29.11 146
2021 Q4 59,210,281 $1,947,305,194 -$73,787,635 $32.87 148
2021 Q3 60,890,488 $2,810,077,563 -$244,072,957 $46.15 157
2021 Q2 65,926,694 $3,632,531,095 +$51,380,893 $55.11 179
2021 Q1 65,233,267 $3,366,007,585 +$56,136,770 $51.64 168
2020 Q4 64,981,734 $2,817,090,446 -$19,419,372 $43.33 189
2020 Q3 65,869,834 $2,304,359,620 -$101,763,130 $35.00 206
2020 Q2 67,492,943 $3,609,431,770 -$76,258,753 $53.48 205
2020 Q1 69,390,256 $2,461,883,479 +$6,215,421 $35.48 188
2019 Q4 69,034,713 $3,296,545,303 +$348,129,625 $47.75 192
2019 Q3 61,888,248 $2,005,330,307 +$38,059,098 $32.40 180
2019 Q2 60,668,045 $3,025,896,532 +$157,762,312 $49.88 182
2019 Q1 60,134,445 $4,055,728,260 +$162,774,480 $67.44 191
2018 Q4 58,006,486 $2,674,145,349 +$50,031,635 $46.11 182
2018 Q3 55,625,309 $4,289,793,406 +$92,816,537 $77.12 199
2018 Q2 54,418,427 $4,583,658,355 -$33,625,899 $84.23 207
2018 Q1 54,830,882 $4,483,993,749 +$716,755,603 $81.78 192
2017 Q4 46,986,627 $2,686,172,197 +$50,530,934 $57.17 173
2017 Q3 46,056,523 $3,074,218,539 +$17,986,293 $66.75 168
2017 Q2 46,127,851 $2,373,318,886 +$325,571,290 $51.45 164
2017 Q1 40,972,190 $2,392,699,790 +$240,606,903 $58.40 154
2016 Q4 39,019,883 $1,628,427,134 +$42,873,951 $41.73 154
2016 Q3 37,828,945 $1,997,518,488 +$255,912,326 $52.82 160
2016 Q2 33,999,654 $1,424,491,193 +$19,274,497 $41.89 150
2016 Q1 33,779,727 $1,371,223,373 +$17,925,029 $40.60 151
2015 Q4 33,010,570 $2,143,167,128 +$96,156,802 $64.92 141
2015 Q3 31,391,017 $2,215,769,820 +$82,761,834 $70.59 149
2015 Q2 30,124,596 $3,347,682,014 +$244,304,306 $111.14 159
2015 Q1 27,958,847 $2,636,827,051 -$36,991,648 $94.30 149
2014 Q4 27,657,103 $3,098,842,918 +$394,968,566 $112.04 142
2014 Q3 24,482,713 $1,502,054,443 +$81,527,891 $61.35 119
2014 Q2 23,591,425 $1,080,804,790 +$140,019,435 $45.82 99
2014 Q1 20,545,950 $804,373,483 +$93,802,312 $39.15 73